Oncology (Switzerland)

SJR Rank #9,930H-index: 112SJR: 0.596Best quartile: Q2
Publisher

S. Karger AG

Country

Switzerland

Type

journal

SJR by Edition

2022202500.250.50.751

Subject Categories

  • Medicine (miscellaneous)Q2
  • Cancer ResearchQ3
  • OncologyQ3

Areas: Biochemistry, Genetics and Molecular Biology · Medicine

Most published research topics

Cancer Treatment and PharmacologyHepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and StudiesDiverse Scientific and Economic StudiesHuman auditory perception and evaluationGastric Cancer Management and OutcomesLung Cancer Treatments and MutationsLung Cancer Research StudiesBreast Cancer Treatment StudiesPancreatic and Hepatic Oncology Research

Source: OpenAlex

Publication Statistics

2025 Docs3-Year DocsCitable Docs070140210280

Documents per Year

2022202504080120160

Detailed Information

ISSN

0030-2414, 1423-0232

SJR Best Quartile

Q2

Region

Western Europe

Citations per Document (2 years)

1.99

References per Document

34.48

Coverage

1948-2026

Scope

Although laboratory and clinical cancer research need to be closely linked, ob­servations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.

Metrics from SCImago Journal Rank 2025. View on SCImago